BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
rs4950928
,
GATA1
,
cell-cell adhesion
,
Obesity
,
Pancreas
,
Nosology
,
Prozac
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
CTLA%204
Summary
General Info
Curated Studies
Most Correlated Studies
There were no matches for CTLA%204
Explore Curated Studies Results
Literature
Most Relevant Literature
A Patient with CTLA-4 Haploinsufficiency with Multiple Autoimmune Presentations: A Case Report.
Increased risk of Graves´ophthalmopathy in patients with increasing TRAb after radioiodine treatment…
Predictive value of immunological markers after bacille Calmette-Guérin induction in bladder cancer.
Correlations of CTLA-4 Exon-1 49 A/G and Promoter Region 318 C/T Polymorphisms with the Therapeutic …
Immune checkpoint inhibitors in infectious disease.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Comparison Study of MDX-010 (CTLA-4) Alone and Combined With DTIC in the Treatment of Metastatic Mel…
A Study of a PD-1/CTLA-4 Bispecific Antibody AK104 in Patients With Metastatic Nasopharyngeal Carcin…
Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory…
Comparison Study of MDX-010 (CTLA-4) Alone and Combined With Docetaxel in the Treatment of Patients …
A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malig…
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ